Facts & figures
As of: January, 2019
1) primarily from public funds (EU, Federal Government, State Government); according to Campus Buch: total funding since 1992, incl. BIMSB
2) primarily from own ressources, since 2001
3) primarily from own ressources
4) since 2009
5) since 2006
6) since 2002
| Research Institutions of Campus Berlin-Buch Employees (total) |
2,151 |
|
| of these: | ||
| Max Delbrück Center for Molecular Medicine (MDC): | 1,646 | |
| Leibniz Institute of Molecular Pharmacology (FMP): | 303 | |
| Klinische Forschung Charité Campus Buch: | 202 | |
| Budget and third-party grants (total)1 | EUR 192 million | |
| Max Delbrück Center for Molecular Medicine (MDC): | EUR 147 million | |
| Leibniz Institute of Molecular Pharmacology (FMP): | EUR 29 million | |
| Klinische Forschung Charité Campus Buch: | EUR 16 million | |
| BiotechPark Berlin-Buch | ||
| Number of companies: | 62 | |
| Employees: | 800 | |
| Annual revenue: Percentage of third-party grants: 3,1% |
EUR 220 million |
|
| Hospitals & Patient-Care Institutions | ||
| Employees (total): of these: |
3,564 | |
| HELIOS Klinikum Berlin-Buch: | 2,700 | |
| Evangelische Lungenklinik: | 325 | |
| Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik): | 89 |
|
| Patient-care institutions: | 450 | |
| Number of patient beds: | 1,267 | |
| Patients per year (inpatient and outpatient): | 220,519 | |
| Total investment volume of these: |
EUR 1.451 billion | |
| Infrastructure Campus Berlin-Buch1 | EUR 624 million | |
| HELIOS Klinikum Berlin-Buch² | EUR 336 million | |
| Evangelische Lungenklinik3 | EUR 49 million | |
| Immanuel Krankenhaus Berlin, Standort Buch (Rheumaklinik)1 | EUR 39 million |
|
| LudwigPark 3 | EUR 45 million | |
| Allées des Châteaux 3 | EUR 23 million | |
| Widerker Vermögensverwaltung (Schlosspark-Passage) 3 | EUR 29 million |
|
| Ludwig Hoffmann Quartier | EUR 152 million |
|
| Housing construction associations (HOWOGE 3,4, EWG 3,5, WBG 3,6 Hau+S 3,5 ) | EUR 154 million |
News Buch Berlin
Inhibitor of lipid kinase PI3KC2α identified as potential new treatment of thrombosis
The lipid kinase PI3KC2α is a potential pharmacological target for the treatment of thrombosis and, possibly, cancer. Researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)...
more ...Dense and permeable: molecular organization of tight junctions decoded
They seal epithelial cells and, under certain conditions, allow the passage of ions and water: Tight junctions form a paracellular barrier in tissues and their dysfunction is associated with diseases ...
more ...Million euro support for MyoPax
MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previous...
more ...Events Buch Berlin
28.09.2022, 14:00
Sport im Bucher Schlosspark für Senior*innen
Kostenfreies und professionell angeleitetes Bewegungsprogramm im Schlosspark Buch
more ...28.09.2022, 16:00
Labor trifft Lehrer: Autoimmunkrankheiten der Niere
Die Fortbildungsreihe Labor trifft Lehrer – digital! bietet einmal im Monat biomedizinische Kurse zur aktuellen Forschung für Lehrerinnen und Lehrer an. Diese finden unter der Leitung von Forschungsgr...
more ...28.09.2022, 18:30
Offener Pilateskurs für alle Nachbarinnen und Nachbarn
Gmeinsam Sport treiben und sich austauschen
more ...
